Biocryst Pharmaceuticals (BCRX) Tax Provisions (2021 - 2026)

Biocryst Pharmaceuticals' Tax Provisions history runs 6 years deep, the most recent figure standing at $1.0 million for Q1 2026.

• Quarterly Tax Provisions rose 38.29% year-over-year to $1.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (up 66.43% YoY) and the FY2025 annual result came in at $3.5 million, up 83.19% from the prior year.
• Tax Provisions was $1.0 million for Q1 2026 at Biocryst Pharmaceuticals, down from $2.2 million in the prior quarter.
• Across five years, Tax Provisions topped out at $2.2 million in Q4 2025 and bottomed at -$1.4 million in Q4 2023.
• A 5-year average of $559058.8 and a median of $671000.0 in 2023 frame the typical range for Tax Provisions.
• Annual changes were most pronounced in 2023 — Tax Provisions tumbled 1982.89% — and 2025, when it soared 714.53%.
• Biocryst Pharmaceuticals' Tax Provisions stood at $76000.0 in 2022, then tumbled by 1982.89% to -$1.4 million in 2023, then jumped by 156.18% to $804000.0 in 2024, then surged by 170.15% to $2.2 million in 2025, then tumbled by 53.78% to $1.0 million in 2026.
• Business Quant data shows BCRX's Tax Provisions at $1.0 million in Q1 2026, $2.2 million in Q4 2025, and -$769000.0 in Q3 2025.